Besides, the de novo oligoclonal expansion of circulating CD19+ plasmablasts in active and relapsing IgG4-RD has been observed, which could be used as a diagnostic biomarker for IgG4-RD independent of serum IgG4 [99]. This evidence concerns the gene CD19 and immunoglobulin G4-related sclerosing disease.